


## AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions of claims in the pending application.

### In the Claims:

1. (Previously presented) A compound of the formula I,



wherein:

X is N or CH;

M is N or CH;

R<sup>1</sup> is hydrogen,

halogen chosen from F, Cl, I and Br,

-(C<sub>1</sub>-C<sub>4</sub>)-alkyl,

-CN,

-CF<sub>3</sub>,

-OR<sup>5</sup>, wherein R<sup>5</sup> is hydrogen or -(C<sub>1</sub>-C<sub>4</sub>)-alkyl,

-N(R<sup>5</sup>)-R<sup>6</sup>, wherein R<sup>5</sup> and R<sup>6</sup> are selected independently from hydrogen and

-(C<sub>1</sub>-C<sub>4</sub>)-alkyl,

-C(O)-R<sup>5</sup>, wherein R<sup>5</sup> is hydrogen or -(C<sub>1</sub>-C<sub>4</sub>)-alkyl, or

-S(O)<sub>x</sub>-R<sup>5</sup>, wherein x is the integer zero, 1 or 2, and wherein R<sup>5</sup> is hydrogen or

-(C<sub>1</sub>-C<sub>4</sub>)-alkyl;

R2 is a heteroaryl radical, which is selected from 3-hydroxypyrrro-2,4-dione, imidazole, imidazolidine, imidazoline, indazole, isothiazole, isothiazolidine, isoxazole, 2-isoxazolidine, isoxazolidine, isoxazolone, morpholine, oxazole, 1,3,4-oxadiazole, oxadiazolidinedione, oxadiazolone, 1,2,3,5-oxathiadiazole-2-oxide, 5-oxo-4,5-dihydro[1,3,4]oxadiazole, 5-oxo-1,2,4-thiadiazole, piperazine, pyrazine, pyrazole, pyrazoline, pyrazolidine, pyridazine, pyrimidine, tetrazole, thiadiazole, thiazole, thiomorpholine, triazole and triazolone, wherein the heteroaryl radical is optionally substituted one, two, or three times by  $-C(O)-R^5$ , wherein  $R^5$  is selected from hydrogen and  $-(C_1-C_4)$ -alkyl,  $-(C_1-C_4)$ -alkyl,  $-O-R^5$ , wherein  $R^5$  is selected from hydrogen and  $-(C_1-C_4)$ -alkyl,  $-N(R^5)-R^6$ , wherein  $R^5$  and  $R^6$  are each selected independently from hydrogen and  $-(C_1-C_4)$ -alkyl, halogen, or a keto radical,  $-C(O)-OR^5$ , wherein  $R^5$  is hydrogen or  $-(C_1-C_4)$ -alkyl, or  $-C(O)-N(R^7)-R^8$ , wherein  $R^7$  and  $R^8$  are each selected independently from hydrogen,  $-(C_1-C_4)$ -alkyl-OH,  $-O-(C_1-C_4)$ -alkyl and  $-(C_1-C_4)$ -alkyl;

R3 is hydrogen or  $-(C_1-C_4)$ -alkyl;

R4 is a heteroaryl radical, which is selected from pyrrole, furan, thiophene, imidazole, pyrazole, oxazole, isoxazole, thiazole, isothiazole, tetrazole, 1,2,3,5-oxathiadiazole-2-oxides, triazolones, oxadiazolone, isoxazolone, oxadiazolidinedione, triazole, 3-hydroxypyrrro-2,4 diones, 5-oxo-1,2,4-thiadiazoles, pyridine, pyrazine, pyrimidine, indole, isoindole, indazole, phthalazine, quinoline, isoquinoline, quinoxaline, quinazoline, cinnoline,  $\beta$ -carboline and benzofused cyclopenta derivatives or cyclohexa derivatives of the heteroaryl radical, wherein the heteroaryl radical is optionally substituted one, two or three times by  $-(C_1-C_5)$ -alkyl,  $-(C_1-C_5)$ -alkoxy, halogen, nitro, amino, trifluoromethyl, hydroxyl, hydroxy- $-(C_1-C_4)$ -alkyl, methylenedioxy, ethylenedioxy, formyl, acetyl, cyano, hydroxycarbonyl, aminocarbonyl or  $-(C_1-C_4)$ -alkoxycarbonyl, or an aryl radical which is selected from phenyl, naphthyl,

1-naphthyl, 2-naphthyl, biphenyl, 2-biphenyl, 3-biphenyl and 4-biphenyl, anthryl and fluorenyl, wherein the aryl radical is optionally substituted one, two, or three times by  $-(C_1-C_5)\text{-alkyl}$ ,  $-(C_1-C_5)\text{-alkoxy}$ , halogen, nitro, amino, trifluoromethyl, hydroxyl, hydroxy- $(C_1-C_4)\text{-alkyl}$ , methylenedioxy, ethylenedioxy, formyl, acetyl, cyano, hydroxycarbonyl, aminocarbonyl or  $-(C_1-C_4)\text{-alkoxycarbonyl}$ ; and

R<sup>11</sup> is hydrogen,

halogen chosen from F, Cl, I and Br,

$-(C_1-C_4)\text{-alkyl}$ ,

-CN,

-CF<sub>3</sub>,

-OR<sup>5</sup>, wherein R<sup>5</sup> is hydrogen or  $-(C_1-C_4)\text{-alkyl}$ ,

-N(R<sup>5</sup>)-R<sup>6</sup>, wherein R<sup>5</sup> and R<sup>6</sup> are selected independently from hydrogen and

$-(C_1-C_4)\text{-alkyl}$ ,

-C(O)-R<sup>5</sup>, wherein R<sup>5</sup> is hydrogen or  $-(C_1-C_4)\text{-alkyl}$ , or

-S(O)<sub>x</sub>-R<sup>5</sup>, wherein x is the integer zero, 1 or 2, and wherein R<sup>5</sup> is hydrogen or

$-(C_1-C_4)\text{-alkyl}$ ,

or a stereoisomer or a mixture of stereoisomers in any ratio of the compound, or a pharmaceutically acceptable salt of the compound.

2. (Previously presented) The compound according to claim 1, wherein

X is N or CH;

M is N or CH;

R<sup>1</sup> is hydrogen,

halogen chosen from F, Cl, I and Br,

$-(C_1-C_4)\text{-alkyl}$ ,

-CN,

-CF<sub>3</sub>,

-OR<sup>5</sup>, wherein R<sup>5</sup> is hydrogen or  $-(C_1-C_4)\text{-alkyl}$ ,

$-N(R^5)-R^6$ , wherein  $R^5$  and  $R^6$  are selected independently from hydrogen and  $-(C_1-C_4)$ -alkyl,  
 $-C(O)-R^5$ , wherein  $R^5$  is hydrogen or  $-(C_1-C_4)$ -alkyl, or  
 $-S(O)_x-R^5$ , wherein  $x$  is the integer zero, 1 or 2, and wherein  $R^5$  is hydrogen or  $-(C_1-C_4)$ -alkyl;

R2 is a heteroaryl radical, which is selected from imidazole, isothiazole, isoxazole, 2-isoxazolidine, isoxazolidine, isoxazolone, 1,3,4-oxadiazole, oxadiazolidinedione, 1,2,3,5-oxadiazolone, oxazole, 5-oxo-4,5-dihydro[1,3,4]-oxadiazole, tetrazole, thiadiazole, thiazole, triazole and triazolone, wherein the heteroaryl radical is optionally substituted one, two, or three times by a keto radical, F, Cl, I, Br, or  $-(C_1-C_2)$ -alkyl, or  $-C(O)-N(R^7)-R^8$ , wherein  $R^7$  and  $R^8$  are each selected independently from hydrogen,  $-(C_1-C_4)$ -alkyl-OH,  $-O-(C_1-C_4)$ -alkyl and  $-(C_1-C_4)$ -alkyl);

R3 is hydrogen, methyl or ethyl;

R4 is a heteroaryl radical which is selected from pyridine, pyrazine, pyrimidine, pyrrole, furan, thiophene, imidazole, pyrazole, oxazole, isoxazole, thiazole, triazole and isothiazole, wherein the heteroaryl radical is optionally substituted one, two or three times by  $-(C_1-C_4)$ -alkyl,  $-(C_1-C_4)$ -alkoxy, F, Cl, I, Br, nitro, amino, trifluoromethyl, hydroxyl, hydroxy- $-(C_1-C_4)$ -alkyl, methylenedioxy, ethylenedioxy, formyl, acetyl, cyano, hydroxycarbonyl, aminocarbonyl or  $-(C_1-C_4)$ -alkoxycarbonyl, or phenyl, wherein the phenyl is optionally substituted one, two or three times by F, Cl, I, Br,  $CF_3$ , -OH,  $-(C_1-C_4)$ -alkyl or  $-(C_1-C_4)$ -alkoxy; and

R11 is hydrogen,

halogen chosen from F, Cl, I and Br,

$-(C_1-C_4)$ -alkyl,

-CN,

$-CF_3$ ,

$-OR^5$ , wherein  $R^5$  is hydrogen or  $-(C_1-C_4)$ -alkyl,


$-N(R^5)-R^6$ , wherein  $R^5$  and  $R^6$  are selected independently from hydrogen and

-(C<sub>1</sub>-C<sub>4</sub>)-alkyl,

-C(O)-R<sup>5</sup>, wherein R<sup>5</sup> is hydrogen or -(C<sub>1</sub>-C<sub>4</sub>)-alkyl, or


-S(O)<sub>x</sub>-R<sup>5</sup>, wherein x is the integer zero, 1 or 2, and wherein R<sup>5</sup> is hydrogen or -(C<sub>1</sub>-C<sub>4</sub>)-alkyl.

3. (Cancelled).
4. (Currently amended) A process for preparing a compound according to claim 1, comprising,
- a) reacting a compound of formula IV,



wherein R<sub>1</sub>, R<sub>2</sub> and R<sub>4</sub> are as defined above,

with an acid chloride or an activated ester of the compound of the formula III,



wherein D<sub>1</sub> is -COOH and R<sub>11</sub>, X, M and R<sub>3</sub> are as defined above, in the presence of a base, or where appropriate, in the presence of a dehydrating agent in solution, and converting the product into a compound of the formula I,

- b) separating the compound of the formula I, which has been prepared by method a) and which, on account of its chemical structure, appears in enantiomeric forms, into the pure enantiomers by means of forming salts with

enantiomerically pure acids or bases, chromatography on chiral stationary phases or derivatization using chiral enantiomerically pure amino acids, separating the resulting diastereomers and eliminating the chiral auxiliary groups, and

- c) isolating the compound of the formula I which has been prepared by methods a) or b) in free form, or
  - d) converting it into ~~physiologically tolerated~~ pharmaceutically acceptable salts when acidic or basic groups are present.
5. (Previously presented) A pharmaceutical composition comprising a pharmaceutically effective amount of the compound according to claim 1 and a pharmaceutically acceptable carrier.

6 to 14. (Canceled)

15. (Previously presented) The compound according to claim 1, including its designated stereochemical center, which is:

N-[(S)-2-diphenylamino-1-(5-oxo-4,5-dihydro[1,3,4]oxadiazol-2-yl)ethyl]-2-(2-methylaminopyrimidin-4-yl)-1H-indole-5-carboxamide,

N-[(S)-1-(5-oxo-4,5-dihydro-1,3,4-oxadiazol-2-yl)-2-(phenylpyridin-2-ylamino)ethyl]-2-(2-methylaminopyrimidin-4-yl)-1H-indole-5-carboxamide,

N-[1-carbamoyl-2-(phenylthiazol-2-ylamino)ethyl]-(S)-2-(2-methylaminopyrimidin-4-yl)-1H-indole-5-carboxamide,

N-[1-methoxycarbonyl-2-(phenylpyridin-2-ylamino)ethyl]-(S)-2-(2-methylaminopyrimidin-4-yl)-1H-indole-5-carboxamide,

(S)-2-[[2-(2-methylaminopyrimidin-4-yl)-1H-indole-5-carbonyl]amino]-3-[phenyl-(4-trifluoromethylpyrimidin-2-yl)amino]propionic acid, or

N-((S)-1-carbamoyl-2-diphenylaminoethyl)-2-(2-methylaminopyrimidin-4-yl)-1H-benzimidazole-5-carboxamide, or

or a pharmaceutically acceptable salt of the compound.

16. (Previously presented) The compound according to claim 1, including its designated stereochemical center, which is:

N-{1-carbamoyl-2-[(4-fluorophenyl)pyridin-2-ylamino]ethyl}-2-(2-methylaminopyrimidin-4-yl)-1H-indole-5-carboxamide,

N-{1-carbamoyl-2-[(4-fluorophenyl)pyridin-2-ylamino]ethyl}-2-(2-aminopyrimidin-4-yl)-1H-indole-5-carboxamide,

N-[2-[(4-fluorophenyl)pyridin-2-ylamino]-1-(4H-[1,2,4]triazol-3-yl)ethyl]-2-(2-methylaminopyrimidin-4-yl)-1H-indole-5-carboxamide,

N-{1-carbamoyl-2-[(phenyl)pyridin-2-ylamino]ethyl}-2-(2-aminopyrimidin-4-yl)-1H-indole-5-carboxamide,

N-{1-carbamoyl-2-[(phenyl)pyrimidin-2-ylamino]ethyl}-2-(2-methylaminopyrimidin-4-yl)-1H-indole-5-carboxamide,

N-[1-(2-hydroxyethylcarbamoyl)-2-(phenylpyrimidin-2-ylamino)ethyl]-2-(2-methylaminopyrimidin-4-yl)-1H-indole-5-carboxamide,

N-{1-carbamoyl-2-[(4-fluorophenyl)-(5-methylpyrimidin-2-yl)amino]ethyl}-2-(2-methylaminopyrimidin-4-yl)-1H-indole-5-carboxamide,

N-{1-carbamoyl-2-[(phenyl)pyrimidin-2-ylamino]ethyl}-2-(2-methylaminopyrimidin-4-yl)-1H-benzimidazole-5-carboxamide, or

N-{1-carbamoyl-2-[(phenyl)pyridin-2-ylamino]ethyl}-2-(2-methylaminopyrimidin-4-yl)-1H-benzimidazole-5-carboxamide,

or a pharmaceutically acceptable salt of the compound.